Zanubrutinib
ZEBUBU22
Phase 2 small_molecule active
Quick answer
Zanubrutinib for Diffuse Large B-cell Lymphoma (DLBCL) is a Phase 2 program (small_molecule) at BeOne Medicines with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BeOne Medicines
- Indication
- Diffuse Large B-cell Lymphoma (DLBCL)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active